← Human Trials & Peer-Reviewed Studies
The influence of growth hormone substitution therapy on erythroid and myeloid progenitor cells and on peripheral blood cells in adult patients with growth hormone deficiency.
Plain-language guide to PMID 9013096 (1996): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 11 patients.
Key Facts
- PMID
- 9013096
- Journal
- European journal of clinical investigation
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Kotzmann H et al. (7 authors)
- DOI
- 10.1046/j.1365-2362.1996.690604.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
It has been reported that hypophysectomized rats exhibit normochromic, normocytic anaemia.
Pancytopenia with impaired DNA synthesis in the bone marrow can be restored in these hypophysectomized rats by syngeneic pituitary grafts placed under the kidney capsule or treatment with growth hormone (GH).
Who Took Part
According to the abstract, 11 patients were involved.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the patients and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
What Was Measured
PubMed files the paper under topics including Erythrocytes, Erythroid Precursor Cells, Erythropoietin, Ferritins, Growth Hormone, Hematocrit and Hematopoietic Stem Cells.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 11 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1996 (European journal of clinical investigation), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.